Annovis Bio
ANVS
42 hedge funds and large institutions have $3.93M invested in Annovis Bio in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
26% more capital invested
Capital invested by funds: $3.13M → $3.93M (+$800K)
18% more call options, than puts
Call options by funds: $306K | Put options by funds: $260K
1.41% less ownership
Funds ownership: 10.71% → 9.3% (-1.4%)
5% less funds holding
Funds holding: 44 → 42 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$179K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$96.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$72.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$60.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$57.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$266K |
| 2 |
Two Sigma Investments
New York
|
-$249K |
| 3 |
Two Sigma Advisers
New York
|
-$139K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$58.5K |
| 5 |
BlackRock
New York
|
-$39.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Squarepoint
New York
| – | -$18.9K | -12,574 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$2.68K | -1,784 | Closed |
|
|
GPFA
53
Game Plan Financial Advisors
Westlake,
Ohio
| – | -$300 | -200 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$3 | -2 | Closed |
|
ANVS Hedge Fund Activity: Q2 2025 in Review
42 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q2 2025, worth a combined $3.93M — up 26% from $3.13M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ANVS and 10 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 12 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $179K. The largest seller was UBS Group, cutting an estimated $266K.
- 42 institutional investors held Annovis Bio (ANVS) as of Q2 2025, down from 44 in Q1 2025.
- Funds reported $3.93M of Annovis Bio stock for Q2 2025, up 26% quarter-over-quarter.
- 10 funds opened new Annovis Bio positions in Q2 2025 and 12 closed out, a net change of -2 holders.
- The largest Annovis Bio buyer in Q2 2025 was Marshall Wace, an estimated $179K added.
- The largest Annovis Bio seller in Q2 2025 was UBS Group, an estimated $266K sold.
Based on aggregated 13F filings for Q2 2025.